Literature DB >> 12208511

Only the soluble form of the scavenger receptor CD163 acts inhibitory on phorbol ester-activated T-lymphocytes, whereas membrane-bound protein has no effect.

Werner Frings1, Jens Dreier, Clemens Sorg.   

Abstract

The extracellular moiety of the hemoglobin/haptoglobin scavenger receptor CD163 (RM3/1 antigen) can be shed from monocytes and is a normal plasma component. We found that in a dose-dependent manner soluble CD163 induces a decrease in CD69 expression, a reduced [(3)H]thymidine uptake and a down-regulated matrix metalloproteinase-9 RNA expression in phorbol myristate acetate-stimulated T-cells. Co-culturing T-cells on transgenic fibroblasts, expressing membrane-bound CD163, yielded no differences compared to culture on non-transfected cells. We conclude that CD163 has at least two distinct functions: the clearance of hemoglobin in its cell-bound form and participation in anti-inflammation as a soluble factor, exhibiting cytokine-like functions.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12208511     DOI: 10.1016/s0014-5793(02)03142-3

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  30 in total

1.  Histiocytic sarcoma with two immunohistopathologically distinct populations.

Authors:  Kanako Wakahashi; Manabu Shimoyama; Yoshio Katayama; Kentaro Minagawa; Kenji Yoshida; Ryohei Sasaki; Shunji Nakayama; Hiroshi Yokozaki; Emmy Yanagita; Tomoo Itoh; Yoshitake Hayashi; Toshimitsu Matsui
Journal:  Int J Hematol       Date:  2010-10-06       Impact factor: 2.490

2.  Expression, by functional proteomics, of spontaneous tolerance in rat orthotopic liver transplantation.

Authors:  Tai-Long Pan; Pei-Wen Wang; Chao-Chen Huang; Shigeru Goto; Chao-Long Chen
Journal:  Immunology       Date:  2004-09       Impact factor: 7.397

3.  Global gene expression profile progression in Gaucher disease mouse models.

Authors:  You-Hai Xu; Li Jia; Brian Quinn; Matthew Zamzow; Keith Stringer; Bruce Aronow; Ying Sun; Wujuan Zhang; Kenneth D R Setchell; Gregory A Grabowski
Journal:  BMC Genomics       Date:  2011-01-11       Impact factor: 3.969

4.  Serum Soluble CD163 and its association with various disease parameters in patients with systemic sclerosis.

Authors:  Waleed Ahmed Salah Eldeen Hassan; Eman Abd Elaleem Baraka; Basant Mohammed Elnady; Tahany Mahmoud Gouda; Nehad Fouad
Journal:  Eur J Rheumatol       Date:  2016-09-01

5.  Evidence for M2 macrophage activation in patients with enthesitis-related arthritis category of juvenile idiopathic arthritis.

Authors:  Shruti Bhattacharya; Akhilesh Yadav; Amita Aggarwal
Journal:  Clin Rheumatol       Date:  2019-02-08       Impact factor: 2.980

Review 6.  Multi-system disorders of glycosphingolipid and ganglioside metabolism.

Authors:  You-Hai Xu; Sonya Barnes; Ying Sun; Gregory A Grabowski
Journal:  J Lipid Res       Date:  2010-03-08       Impact factor: 5.922

7.  Soluble CD163 serum levels are elevated and correlated with IL-12 and CXCL10 in patients with long-standing rheumatoid arthritis.

Authors:  Claudia Jude; Doru Dejica; Gabriel Samasca; Loredana Balacescu; Ovidiu Balacescu
Journal:  Rheumatol Int       Date:  2012-08-22       Impact factor: 2.631

8.  CD163 expression confers susceptibility to porcine reproductive and respiratory syndrome viruses.

Authors:  Jay G Calvert; David E Slade; Shelly L Shields; Rika Jolie; Ramasamy M Mannan; Robert G Ankenbauer; Siao-Kun W Welch
Journal:  J Virol       Date:  2007-05-09       Impact factor: 5.103

Review 9.  Mycobacteria and other environmental organisms as immunomodulators for immunoregulatory disorders.

Authors:  G A W Rook; V Adams; J Hunt; R Palmer; R Martinelli; L Rosa Brunet
Journal:  Springer Semin Immunopathol       Date:  2003-10-08

10.  Human cytomegalovirus interleukin-10 polarizes monocytes toward a deactivated M2c phenotype to repress host immune responses.

Authors:  Selmir Avdic; John Z Cao; Brian P McSharry; Leighton E Clancy; Rebecca Brown; Megan Steain; David J Gottlieb; Allison Abendroth; Barry Slobedman
Journal:  J Virol       Date:  2013-07-17       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.